The interaction of ifosfamide and aprepitant in gynecologic malignancies☆
نویسندگان
چکیده
•Aprepitant combined with ifosfamide may lead to encephalopathy.•Aprepitant-ifosfamide induced encephalopathy was of short duration in these cases.
منابع مشابه
Two Cases of Fatal Encephalopathy Related to Ifosfamide: An Adverse Role of Aprepitant?
Ifosfamide is used in the treatment of sarcomas and other tumors. It sometimes provokes encephalopathy, which is a serious complication even if it is usually reversible within 48-72 h after drug cessation. Ifosfamide is required to be activated by hepatic cytochrome P450 (CYP), especially the 3A4 subtype, leading to 4-hydroxy-ifosfamide. Ifosfamide is also converted by CYP3A4 to inactive but ne...
متن کاملAntiemetic neurokinin-1 antagonist aprepitant and ifosfamide-induced encephalopathy.
We report the occurrence of an acute encephalopathy following ifosfamide infusion, that we believe directly triggered by aprepitant (Emend, Merck & Co., Inc.). Aprepitant, the first neurokinin-1 receptor antagonist, is a new antiemetic indicated for highly and moderately emetogenic chemotherapy, in association with 5-HT3 receptor antagonists and corticosteroids. A 57-year-old woman presented wi...
متن کاملTreatment of Ifosfamide -induced Encephalopathy with Methylene Blue in an Adolescent with Relapsed Acute Lymphoblastic Leukemia: a case report
Ifosfamide is one of the most important chemotherapeutic agents used for the treatment of numerous types of malignancies. Neurotoxicity is one of its life-threatening complications and is potentially fatal. In this paper we present a case of severe ifosfamide- induced encephalopathy in an adolescent with acute lymphoblastic leukemia in whom treatment with methylene blue led to complete improvem...
متن کاملEfficacy analysis of the aprepitant-combined antiemetic prophylaxis for non-round cell soft-tissue sarcoma patients received adriamycin and ifosfamide therapy
Appropriate antiemetic prophylaxis for moderately emetogenic chemotherapy in patients with non-round cell soft-tissue sarcomas (NRC-STS) remains unclear. We retrospectively investigated efficacy and safety of aprepitant-combined antiemetic prophylaxis in patients with NRC-STS receiving adriamycin plus ifosfamide (AI) therapy. Forty NRC-STS patients were enrolled, their median age was 50 years (...
متن کاملA randomized controlled study evaluating the efficacy of aprepitant for highly/moderately emetogenic chemotherapies in hematological malignancies.
Chemotherapy-induced nausea and vomiting (CINV) is a serious complication of treatments of hematological malignancies. Although aprepitant, an NK1 receptor antagonist, has been shown to control CINV in highly emetogenic therapies for solid tumors, the antiemetic effect of this agent in hematological chemotherapies is not well established. In this randomized controlled trial, we examined the add...
متن کامل